Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study

The short-chain fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial metabolites that mediate the interaction between the diet, the microbiota and the host. In the present study, the systemic availability of SCFAs and their incorporation into biologically relevant molecules was quantified. Known amounts of 13C-labelled acetate, propionate and butyrate were introduced in the colon of 12 healthy subjects using colon delivery capsules and plasma levels of 13C-SCFAs 13C-glucose, 13C-cholesterol and 13C-fatty acids were measured. The butyrate-producing capacity of the intestinal microbiota was also quantified. Systemic availability of colonic-administered acetate, propionate and butyrate was 36%, 9% and 2%, respectively. Conversion of acetate into butyrate (24%) was the most prevalent interconversion by the colonic microbiota and was not related to the butyrate-producing capacity in the faecal samples. Less than 1% of administered acetate was incorporated into cholesterol and <15% in fatty acids. On average, 6% of colonic propionate was incorporated into glucose. The SCFAs were mainly excreted via the lungs after oxidation to 13CO2, whereas less than 0.05% of the SCFAs were excreted into urine. These results will allow future evaluation and quantification of SCFA production from 13C-labelled fibres in the human colon by measurement of 13C-labelled SCFA concentrations in blood

The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics

In May 2019, the International Scientific Association for Probiotics and Prebiotics (ISAPP) convened a panel of nutritionists, physiologists and microbiologists to review the definition and scope of synbiotics. The panel updated the definition of a synbiotic to “a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host”. The panel concluded that defining synbiotics as simply a mixture of probiotics and prebiotics could suppress the innovation of synbiotics that are designed to function cooperatively. Requiring that each component must meet the evidence and dose requirements for probiotics and prebiotics individually could also present an obstacle. Rather, the panel clarified that a complementary synbiotic, which has not been designed so that its component parts function cooperatively, must be composed of a probiotic plus a prebiotic, whereas a synergistic synbiotic does not need to be so. A synergistic synbiotic is a synbiotic for which the substrate is designed to be selectively utilized by the co-administered microorganisms. This Consensus Statement further explores the levels of evidence (existing and required), safety, effects upon targets and implications for stakeholders of the synbiotic concept

Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers : a double-blind, randomised, placebo-controlled, cross-over trial

Wheat bran extract (WBE) is a food-grade soluble fibre preparation that is highly enriched in arabinoxylan oligosaccharides. In this placebo-controlled cross-over human intervention trial, tolerance and effects on colonic protein and carbohydrate fermentation were studied. After a 1-week run-in period, sixty-three healthy adult volunteers consumed 3, 10 and 0 g WBE/d for 3 weeks in a random order, with 2 weeks' washout between each treatment period. Fasting blood samples were collected at the end of the run-in period and at the end of each treatment period for analysis of haematological and clinical chemistry parameters. Additionally, subjects collected a stool sample for analysis of microbiota, SCFA and pH. A urine sample, collected over 48 h, was used for analysis of p-cresol and phenol content. Finally, the subjects completed questionnaires scoring occurrence frequency and distress severity of eighteen gastrointestinal symptoms. Urinary p-cresol excretion was significantly decreased after WBE consumption at 10 g/d. Faecal bifidobacteria levels were significantly increased after daily intake of 10 g WBE. Additionally, WBE intake at 10 g/d increased faecal SCFA concentrations and lowered faecal pH, indicating increased colonic fermentation of WBE into desired metabolites. At 10 g/d, WBE caused a mild increase in flatulence occurrence frequency and distress severity and a tendency for a mild decrease in constipation occurrence frequency. In conclusion, WBE is well tolerated at doses up to 10 g/d in healthy adults volunteers. Intake of 10 g WBE/d exerts beneficial effects on gut health parameters

Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics

In December 2016, a panel of experts in microbiology, nutrition and clinical research was convened by the International Scientific Association for Probiotics and Prebiotics to review the definition and scope of prebiotics. Consistent with the original embodiment of prebiotics, but aware of the latest scientific and clinical developments, the panel updated the definition of a prebiotic: a substrate that is selectively utilized by host microorganisms conferring a health benefit. This definition expands the concept of prebiotics to possibly include non-carbohydrate substances, applications to body sites other than the gastrointestinal tract, and diverse categories other than food. The requirement for selective microbiota-mediated mechanisms was retained. Beneficial health effects must be documented for a substance to be considered a prebiotic. The consensus definition applies also to prebiotics for use by animals, in which microbiota-focused strategies to maintain health and prevent disease is as relevant as for humans. Ultimately, the goal of this Consensus Statement is to engender appropriate use of the term ‘prebiotic’ by relevant stakeholders so that consistency and clarity can be achieved in research reports, product marketing and regulatory oversight of the category. To this end, we have reviewed several aspects of prebiotic science including its development, health benefits and legislation

Radiopharmaceuticals: Recent Developments and Trends 247 15 Radiopharmaceuticals: Recent Developments and Trends 15.1 Production of Radiopharmaceuticals, Quality Control and Availability

Radionuclides used in nuclear medicine are mostly artificial ones. They are primarily produced in a reactor or cyclotron and supplied by commercial companies to individual nuclear medicine departments and institutions. On the other hand, some radionuclides, in particular short-lived ones, are available at any time due to the availability of appropriate radionuclide generators. By far the most important generator in nuclear medicine is the 99 Mo/ 99m Tc generator, which has led to the almost unlimited availability of 99m Tc. Together with the excellent radiation characteristics of 99m Tc and the commercial availability of efficient and licensed labeling kits, this generator lies at the base of contemporary nuclear medicine practice. The very short-lived positron-emitting radionuclides used in clinical PET [ 11 C (t ½ = 20.38 min), 13 N (t ½ = 9.96 min) and 15 O (t ½ = 122.2 s)] are only available at or near institutions which have cyclotron facilities and can not be supplied to remote institutions or hospitals due to their rapid decay. Since facilities with a cyclotron and radiochemistry laboratory are expensive, they are not evenly spread worldwide, although their number has increased significantly in recent years. A steadily growing number of PET centers performs clinical imaging but does not have a cyclotron. These sites are mostly limited to the use of radiotracers labeled with fluorine-18 (t ½ = 109.8 min), provided by nearby facilities. Currently, mainly 18 Ffluorodeoxyglucose ( 18 FDG) is produced in these facilities, increasingly under 'good manufacturing practice' (GMP) conditions, and dispensed to PET imaging facilities in the area. It can be foreseen that soon other fluorine-18 labeled PET radiopharmaceuticals will be distributed through the logistic channels that have been set up for 18 FDG distribution. There is a growing interest in using PET radiopharmaceuticals labeled with gallium-68, a radio-CONTENT

Further investigations on the role of diet-induced thermogenesis in the regulation of feed intake in chickens: Comparison of adult cockerels of lines selected for high or low residual feed intake

The main objective of this study was to investigate the role of diet-induced thermogenesis (DIT) in feed intake regulation in cockerels selected for high (R+) or low (R-) residual feed intake. The selection criterion was defined as the difference between observed feed intake and feed intake predicted by regression between feed intake and BW, BW gain, and egg mass production. Furthermore, the effect of genotype on postprandial oxidation of U-(13) C-6-glucose, decarboxylation of 1-C-13 (1)-Leu, and key metabolites and hormones was analyzed. Thirty 24-wk-old cockerels of both lines were kept in battery cages under standard conditions on a commercial diet. Three cockerels per genotype were examined twice weekly from wk 30 through 34 in open-circuit respiratory cells. After adaptation, cockerels were feed deprived for 24 h and heat production was measured. During the subsequent 7-h refeeding period, DIT and feed intake, as well as glucose oxidation and Leu decarboxylation were assessed by using breath tests. Blood samples were collected after fasting and refeeding. Finally, 10 animals per genotype were killed to record abdominal fat weight. Body composition of 6 different chickens per genotype was determined by using dual-energy x-ray absorptiometry. During feed deprivation, the R+ cockerels had a significantly higher heat production than their R- counterparts, which was even more pronounced during refeeding. Consequently, the R+ cockerels had a significantly increased DIT and a higher feed intake than the R- cockerels. Thus, no evidence of a feedback effect of DIT on feed intake was observed. The oxidation of U-(13) C6-glucose was significantly higher in the R+ cockerels, confirming their higher respiratory quotient values and the augmented fat deposition in the R- chickens, as assessed by abdominal fat weight and dual-energy x-ray absorptiometry measurements. No significant genotype effect on 1-C-13 (1)-Leu decarboxylation was observed, despite increased circulating uric acid levels in the R+ chickens. Genotype did not influence plasma levels of triglycerides, free fatty acids, glucose, triiodothyronine, or thyroxine after refeeding, whereas plasma leptin levels were significantly higher in the R+ cockerels.status: publishe

Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides

Arabinoxylans (AX) from cereals are cell wall components that constitute an important part of the dietary fiber intake in humans. Enzymatic hydrolysis of AX yields arabinoxylan-oligosaccharides (AXOS), consisting of arabinoxylooligosaccharides and xylooligosaccharides (XOS). This reaction takes place in the production of AXOS and of cereal-derived food products such as bread and beer, as well as in the colon upon ingestion of AX. This review mainly focuses on the available evidence that AXOS and XOS exert prebiotic effects in the colon of humans and animals through selective stimulation of beneficial intestinal microbiota. In addition, in vitro experiments and in vivo intervention studies on animals or humans are discussed that have investigated potential health-related effects resulting from the dietary intake of AX, AXOS, or XOS

The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Prebiotics

In December 2016, a panel of experts in microbiology, nutrition and clinical research was convened by the International Scientific Association for Probiotics and Prebiotics to review the definition and scope of prebiotics. Consistent with the original embodiment of prebiotics, but aware of the latest scientific and clinical developments, the panel updated the definition of a prebiotic: a substrate that is selectively utilized by host microorganisms conferring a health benefit. This definition expands the concept of prebiotics to possibly include non-carbohydrate substances, applications to body sites other than the gastrointestinal tract, and diverse categories other than food. The requirement for selective microbiota-mediated mechanisms was retained. Beneficial health effects must be documented for a substance to be considered a prebiotic. The consensus definition applies also to prebiotics for use by animals, in which microbiota-focused strategies to maintain health and prevent disease is as relevant as for humans. Ultimately, the goal of this Consensus Statement is to engender appropriate use of the term ‘prebiotic’ by relevant stakeholders so that consistency and clarity can be achieved in research reports, product marketing and regulatory oversight of the category. To this end, we have reviewed several aspects of prebiotic science including its development, health benefits and legislation